CIAS
ALXN

Capital Investment Advisory Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital Investment Advisory Services’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100
Closed -$10K – 1369
2019
Q3 		$10K Hold
100
– – ﹤0.01% 996
2019
Q2 		$12K Buy
+100
New +$12.9K ﹤0.01% 931
2019
Q1 		– Sell
-33
Closed -$3K – 1304
2018
Q4 		$3K Buy
+33
New +$3.9K ﹤0.01% 1031

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Investment Advisory Services's ALXN Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 100 shares — an estimated $10K sold.

Capital Investment Advisory Services first reported a position in ALXN in Q4 2018 and held it in 3 quarters. The position peaked at $12K in Q2 2019. 668 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Capital Investment Advisory Services reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 100 Alexion Pharmaceuticals shares in Q4 2019, an estimated $10K.
  • Capital Investment Advisory Services first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Capital Investment Advisory Services's Alexion Pharmaceuticals position peaked at $12K in Q2 2019.
  • 668 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.